Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Impact of daptomycin resistance on Staphylococcus aureus virulence.

Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC Jr, Eliopoulos GM, Peleg AY.

Virulence. 2015;6(2):127-31. doi: 10.1080/21505594.2015.1011532.

2.

Tedizolid: a novel oxazolidinone for Gram-positive infections.

Moellering RC Jr.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S1-3. doi: 10.1093/cid/cit658. Review. No abstract available.

PMID:
24343826
3.

Daptomycin In Vitro Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.

Gasch O, Pillai SK, Dakos J, Miyakis S, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2013 Sep;57(9):4537-4539. doi: 10.1128/AAC.00799-13. Epub 2013 Jun 24.

4.

Towards squalamine mimics: synthesis and antibacterial activities of head-to-tail dimeric sterol-polyamine conjugates.

Chen WH, Wennersten C, Moellering RC Jr, Regen SL.

Chem Biodivers. 2013 Mar;10(3):385-93. doi: 10.1002/cbdv.201100431.

PMID:
23495155
5.

Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus.

Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC Jr, Eliopoulos GM, Peleg AY.

J Infect Dis. 2012 Jun;205(11):1677-87. doi: 10.1093/infdis/jis252. Epub 2012 Apr 5.

6.

Introduction: Solving the clinical problem of vancomycin resistance.

Moellering RC Jr, Ferraro MJ.

Clin Infect Dis. 2012 Apr;54 Suppl 3:S201-2. doi: 10.1093/cid/cir1046. No abstract available.

PMID:
22431849
7.

Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC Jr, Eliopoulos GM.

PLoS One. 2012;7(1):e28316. doi: 10.1371/journal.pone.0028316. Epub 2012 Jan 6.

8.

MRSA: the first half century.

Moellering RC Jr.

J Antimicrob Chemother. 2012 Jan;67(1):4-11. doi: 10.1093/jac/dkr437. Epub 2011 Oct 18. Review.

PMID:
22010206
9.

Advances in antibacterial therapy.

Moellering RC Jr.

Transplant Proc. 2011 Jul-Aug;43(6):2441-2. doi: 10.1016/j.transproceed.2011.06.023. Review.

PMID:
21839287
10.

Introduction: fusidic acid enters the United States.

Moellering RC Jr, Corey GR, Grayson ML.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S467-8. doi: 10.1093/cid/cir171. No abstract available.

PMID:
21546622
11.

Case records of the Massachusetts General Hospital. Case 2-2011. A 30-year-old woman with shock after treatment of a furuncle.

Moellering RC Jr, Abbott GF, Ferraro MJ.

N Engl J Med. 2011 Jan 20;364(3):266-75. doi: 10.1056/NEJMcpc1003886. No abstract available.

PMID:
21247318
12.

NDM-1--a cause for worldwide concern.

Moellering RC Jr.

N Engl J Med. 2010 Dec 16;363(25):2377-9. doi: 10.1056/NEJMp1011715. No abstract available.

13.

The problem of complicated skin and skin structure infections: the need for new agents.

Moellering RC Jr.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv3-8. doi: 10.1093/jac/dkq250.

PMID:
21115452
14.

Discovering new antimicrobial agents.

Moellering RC Jr.

Int J Antimicrob Agents. 2011 Jan;37(1):2-9. doi: 10.1016/j.ijantimicag.2010.08.018. Epub 2010 Nov 13. Review.

PMID:
21075608
15.

Update: A 39-year-old man with a skin infection.

Moellering RC, Mattson-DiCecca AA, Reynolds EE.

JAMA. 2010 Jan 6;303(1):64. doi: 10.1001/jama.2009.1960. No abstract available.

PMID:
20051570
16.

Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Joukhadar C, Pillai S, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2010 Feb;54(2):773-7. doi: 10.1128/AAC.00348-09. Epub 2009 Nov 23.

17.
18.

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW.

Clin Infect Dis. 2009 Oct 15;49(8):1169-74. doi: 10.1086/605636.

PMID:
19769538
19.

New treatments for multiply drug-resistant Gram-positive bacteria.

Moellering RC Jr.

J Infect. 2009 Sep;59 Suppl 1:S1-3. doi: 10.1016/S0163-4453(09)60002-5. No abstract available.

PMID:
19766884
20.

What is inadequate antibacterial therapy?

Moellering RC Jr.

Clin Infect Dis. 2009 Oct 1;49(7):1006-8. doi: 10.1086/605556. No abstract available.

PMID:
19719418
21.

Competition of hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus strains in hospitals.

Webb GF, Horn MA, D'Agata EM, Moellering RC Jr, Ruan S.

J Biol Dyn. 2010 Jan;4(1):115-29.

22.

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP.

Clin Infect Dis. 2009 Aug 1;49(3):325-7. doi: 10.1086/600877. Erratum in: Clin Infect Dis. 2009 Nov 1;49(9):1465.

PMID:
19569969
23.

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus.

Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Herrmann M, Hoen B, Karchmer AW, Kobayashi Y, Kozlov RS, Lew D, MirĂ³ JM, Moellering RC Jr, Moreillon P, Peters G, Rubinstein E, Seifert H, Corey GR.

Clin Infect Dis. 2009 May 15;48 Suppl 4:S260-70. doi: 10.1086/598185.

PMID:
19374582
24.

Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.

Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC Jr, Mylonakis E.

Antimicrob Agents Chemother. 2009 Jun;53(6):2605-9. doi: 10.1128/AAC.01533-08. Epub 2009 Mar 30.

25.

Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals.

D'Agata EM, Webb GF, Horn MA, Moellering RC Jr, Ruan S.

Clin Infect Dis. 2009 Feb 1;48(3):274-84.

26.

Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection.

Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM.

J Infect Dis. 2009 Feb 15;199(4):532-6. doi: 10.1086/596511.

27.

Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa.

Peleg AY, Tilahun Y, Fiandaca MJ, D'Agata EM, Venkataraman L, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2009 Mar;47(3):830-2. doi: 10.1128/JCM.01724-08. Epub 2008 Dec 30.

28.

Drug interactions modulate the potential for evolution of resistance.

Michel JB, Yeh PJ, Chait R, Moellering RC Jr, Kishony R.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14918-23. doi: 10.1073/pnas.0800944105. Epub 2008 Sep 24.

29.

Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans.

Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC Jr, Mylonakis E.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14585-90. doi: 10.1073/pnas.0805048105. Epub 2008 Sep 15.

30.

Clinical decisions. Management of skin and soft-tissue infection.

Chambers HF, Moellering RC Jr, Kamitsuka P.

N Engl J Med. 2008 Sep 4;359(10):1063-7. doi: 10.1056/NEJMclde0708359. No abstract available.

PMID:
18768953
31.

Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Gqada Z, Marais B, Wasserman E, Bamford C, Orth H, Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2008 Jul;46(7):2471; author reply 2471-2. doi: 10.1128/JCM.00519-08. No abstract available.

32.

Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.

Sakoulas G, Moellering RC Jr.

Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S360-7. doi: 10.1086/533592. Review.

PMID:
18462091
33.

Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection.

Moellering RC Jr.

Clin Infect Dis. 2008 Apr 1;46(7):1032-7. doi: 10.1086/529445. Review.

PMID:
18444820
34.

Telithromycin and the FDA: implications for the future.

Shlaes DM, Moellering RC.

Lancet Infect Dis. 2008 Feb;8(2):83-5. doi: 10.1016/S1473-3099(08)70002-1. No abstract available.

PMID:
18222155
35.

A 39-year-old man with a skin infection.

Moellering RC Jr.

JAMA. 2008 Jan 2;299(1):79-87. Epub 2007 Dec 4.

PMID:
18056894
36.

Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2008 Jan;46(1):220-4. Epub 2007 Nov 14.

37.

Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L; American Society for Microbiology.

Am J Infect Control. 2007 Nov;35(9):S1-23; quiz S24-6. Review.

PMID:
17980231
38.

Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.

Tsakris A, Pillai SK, Gold HS, Thauvin-Eliopoulos C, Venkataraman L, Wennersten C, Moellering RC Jr, Eliopoulos GM.

J Antimicrob Chemother. 2007 Sep;60(3):649-51. Epub 2007 Jul 10.

PMID:
17623697
39.

Genetic diversity among Enterococcus faecalis.

McBride SM, Fischetti VA, Leblanc DJ, Moellering RC Jr, Gilmore MS.

PLoS One. 2007 Jul 4;2(7):e582.

40.

Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L.

Am J Med. 2007 Jul;120(7):S4-25; quiz S26-8.

PMID:
17602911
41.
42.

Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2007 Jun;51(6):2223-5. Epub 2007 Apr 2.

43.

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2006 Apr;50(4):1581-5.

44.

The growing menace of community-acquired methicillin-resistant Staphylococcus aureus.

Moellering RC Jr.

Ann Intern Med. 2006 Mar 7;144(5):368-70. No abstract available.

PMID:
16520479
45.

Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.

Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM.

J Antimicrob Chemother. 2006 Apr;57(4):699-704. Epub 2006 Feb 7.

PMID:
16464892
46.

The management of infections due to drug-resistant gram-positive bacteria.

Moellering RC Jr.

Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):777-9. Review. No abstract available.

PMID:
16362382
47.

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.

Sakoulas G, Moellering RC Jr, Eliopoulos GM.

Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S40-50. Review.

PMID:
16323119
48.

Vancomycin: a 50-year reassessment.

Moellering RC Jr.

Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S3-4. No abstract available.

PMID:
16323117
49.

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2005 Jul;49(7):3034-9.

50.

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Sakoulas G, Eliopoulos GM, Fowler VG Jr, Moellering RC Jr, Novick RP, Lucindo N, Yeaman MR, Bayer AS.

Antimicrob Agents Chemother. 2005 Jul;49(7):2687-92.

Supplemental Content

Loading ...
Support Center